Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2020-12-02 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma publie son calendrier financier pour 2021
Report Publication Announcement Classification · 98% confidence The document is titled "INNATE PHARMA PUBLIE SON CALENDRIER FINANCIER POUR 2021" (Innate Pharma Publishes its Financial Calendar for 2021). It explicitly lists future dates for key financial announcements, such as the publication of annual results (March 18), quarterly revenue (May 11, November 16), half-year results (September 15), and the Annual General Meeting (May 28). This document is an announcement detailing the schedule of future corporate events and report releases, rather than the reports themselves (like 10-K or IR). According to Rule 2, when a document announces the publication of reports, it should be classified as a Report Publication Announcement (RPA).
2020-12-02 French
Innate Pharma 2021 financial calendar
Report Publication Announcement Classification · 98% confidence The document is titled 'INNATE PHARMA 2021 FINANCIAL CALENDAR' and explicitly lists dates for the 'Publication of 2020 financial statements', 'Publication of revenue for 1Q2021', and 'Publication of half year financial statements'. It also mentions the date for the 'Annual General Shareholders Meeting' (May 28, 2021). Crucially, the document itself is an announcement *about* future reporting dates, not the reports themselves. Since it announces the schedule for various financial reports and the AGM, and the document length is relatively short (5163 chars) and serves as a notice, it best fits the category for announcing the publication of reports. The most fitting category for announcing the release schedule of financial reports and corporate events is Report Publication Announcement (RPA).
2020-12-02 English
FORM 6-K
Foreign Filer Report
2020-11-17 English
Half-year financial report - June 30, 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR FINANCIAL REPORT JUNE 30, 2020' and contains comprehensive interim condensed consolidated financial statements, management review, and auditor review reports. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2020
2020-11-17 English
Rapport financier semestriel au 30 juin 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel' (Half-Year Financial Report) for Innate Pharma S.A. for the period ending June 30, 2020. It contains comprehensive financial statements, including a consolidated balance sheet, income statement, cash flow statement, and notes to the financial statements, as well as a management report on activities. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. H2 2020
2020-11-17 French
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au troisième trimestre 2020
Earnings Release Classification · 95% confidence The document is a press release from Innate Pharma announcing its financial results and portfolio updates for the third quarter of 2020. It provides key highlights, including revenue figures, cash position, and clinical trial updates. While it contains financial data, it is structured as an initial announcement (Earnings Release) rather than a full, comprehensive interim financial report. It follows the standard format for an earnings release, summarizing performance for the period and providing management commentary. 9M 2020
2020-11-17 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.